Clinical Trial Update: A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating different doses of sitagliptin (MK-0431) in participants with type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (Januvia) (sitagliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type II Diabetes Mellitus | Phase 2 | Status: COMPLETED